

Claims

1. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD and asthma, hematological diseases, cancer, gastrointestinal diseases and inflammation in a mammal comprising the steps of
- 5
- i) contacting a test compound with a GHS polypeptide,
- 10
- ii) detect binding of said test compound to said GHS polypeptide.
2. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD and asthma, hematological diseases, cancer, gastrointestinal diseases and inflammation in a mammal comprising the steps of
- 15
- i) determining the activity of a GHS polypeptide at a certain concentration of a test compound or in the absence of said test compound,
- 20
- ii) determining the activity of said polypeptide at a different concentration of said test compound.
- 25
3. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD and asthma, hematological diseases, cancer, gastrointestinal diseases and inflammation in a mammal comprising the steps of
- 30

- i) determining the activity of a GHS polypeptide at a certain concentration of a test compound,
- ii) determining the activity of a GHS polypeptide at the presence of a compound known to be a regulator of a GHS polypeptide.
4. The method of any of claims 1 to 3, wherein the step of contacting is in or at the surface of a cell.
5. The method of any of claims 1 to 3, wherein the cell is in vitro.
6. The method of any of claims 1 to 3, wherein the step of contacting is in a cell-free system.
7. The method of claims 1 to 3, wherein the polypeptide is coupled to a detectable label.
8. The method of any of claims 1 to 3, wherein the compound is coupled to a detectable label.
9. The method of any of claims 1 to 3, wherein the test compound displaces a ligand which is first bound to the polypeptide.
10. The method of any of claims 1 to 3, wherein the polypeptide is attached to a solid support.
11. The method of any of claims 1 to 3, wherein the compound is attached to a solid support.
12. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular

diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD and asthma, hematological diseases, cancer, gastro-intestinal diseases and inflammation in a mammal comprising the steps of

- 5 - i) contacting a test compound with a GHS polynucleotide,
- ii) detect binding of said test compound to said GHS polynucleotide.
13. The method of claim 12 wherein the nucleic acid molecule is RNA.
- 10 14. The method of claim 12 wherein the contacting step is in or at the surface of a cell.
15. The method of claim 12 wherein the contacting step is in a cell-free system.
16. The method of claim 12 wherein polynucleotide is coupled to a detectable label.
17. The method of claim 12 wherein the test compound is coupled to a detectable label.
- 20 18. A method of diagnosing a disease comprised in a group of diseases consisting of cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD and asthma, hematological diseases, cancer, gastro-intestinal diseases and inflammation in a mammal comprising the steps of
- 25 i) determining the amount of a GHS polynucleotide in a sample taken from said mammal,

- ii) determining the amount of GHS polynucleotide in healthy and/or diseased mammals.

5 19. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD and asthma, hematological diseases, cancer, gastro-intestinal diseases and inflammation in a mammal comprising a therapeutic agent which binds to a GHS polypeptide.

10

20. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD and asthma, hematological diseases, cancer, gastro-intestinal diseases and inflammation in a mammal comprising a therapeutic agent which regulates the activity of a GHS polypeptide.

15

21. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD and asthma, hematological diseases, cancer, gastro-intestinal diseases and inflammation in a mammal comprising a therapeutic agent which regulates the activity of a GHS polypeptide, wherein said therapeutic agent is

20

- 25 i) a small molecule,
ii) an RNA molecule,
iii) an antisense oligonucleotide,
iv) a polypeptide,
v) an antibody, or
30 vi) a ribozyme.

22. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD and asthma, hematological diseases, cancer, gastro-intestinal diseases and inflammation in a mammal comprising a GHS polynucleotide.
23. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD and asthma, hematological diseases, cancer, gastro-intestinal diseases and inflammation in a mammal comprising a GHS polypeptide.
24. Use of regulators of a GHS for the preparation of a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD and asthma, hematological diseases, cancer, gastro-intestinal diseases and inflammation in a mammal.
25. Method for the preparation of a pharmaceutical composition useful for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD and asthma, hematological diseases, cancer, gastro-intestinal diseases and inflammation in a mammal comprising the steps of
- i) identifying a regulator of GHS,
 - ii) determining whether said regulator ameliorates the symptoms of a disease comprised in a group of diseases consisting of cardiovascular diseases, disorders of the peripheral and central nervous system,

respiratory diseases like COPD and asthma, hematological diseases, cancer, gastro-intestinal diseases and inflammation in a mammal; and

iii) combining of said regulator with an acceptable pharmaceutical carrier.

5

26. Use of a regulator of GHS for the regulation of GHS activity in a mammal having a disease comprised in a group of diseases consisting of cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD and asthma, hematological diseases, cancer, gastro-

10

intestinal diseases and inflammation.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.